Tomorrow’s Tech, Today: Innovation That Moves Us Forward
- Reid Hoffman was involved when Microsoft invested early in OpenAI and was one of OpenAI’s original investors.
- He left OpenAI's board in 2023 citing conflicts and witnessed Microsoft's acqui-hire with Inflection AI that brought in Mustafa Suleyman.
- Reid Hoffman says he will return to founder mode to focus on his AI drug discovery startup Manus, where he is co-founder and investor.
- Manus pursues Move 37 AI to exceed human creativity in chemistry, aiming at cancer treatments under CEO Dr. Siddhartha Mukherjee, a Pulitzer winner.
After a very profitable decade on Microsoft’s board, Reid Hoffman is stepping down, the company announced Thursday. Hoffman joined the board after Microsoft bought his company LinkedIn for $26.2 billion in 2016.
Hoffman was on Microsoft’s board when it invested its first $1 billion into OpenAI in 2019. Hoffman was one of OpenAI’s original investors and served on the model maker’s board until he stepped down in 2023, citing too many potential conflicts of interest to continue. He was also on Microsoft’s board when the tech giant entered into one of those non-acquisition, acqui-hire deals for $650 million with his AI startup Inflection AI. Microsoft hired Inflection co-founder Mustafa Suleyman through that deal.
Hoffman said on a recent episode of his “Possible” podcast, while talking with Microsoft CEO Satya Nadella, that he’s ready to go “founder mode” with his latest AI startup, Manus. Manus is a drug discovery company that raised over $50 million through a couple of seed rounds last year. Hoffman is an investor, as is General Catalyst.
Hoffman is cited as a co-founder of Manus and chairman of the board, not the CEO, though. That job belongs to Dr. Siddhartha Mukherjee, a physician, biologist, and Pulitzer Prize-winning author of the 2011 book “The Emperor of All Maladies: A Biography of Cancer.”
Still, Hoffman said he’s excited to give Manus more attention.
“One of the things I realized over the last month was that, we’re seeing such progress with Manus. I need to get back to founder mode,” he said. He believes the startup is making progress on “Move 37” AI, meaning AI that supersedes human creativity in chemistry, especially to combat various cancers, he added.
Read the full article on the original site
